Crinetics Pharmaceuticals, Inc. will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market closes. The company's management will host a conference call at 4:30 p.m. ET to discuss the financial results and provide a business update.

Conference Call Details

Investors and interested parties can access the conference call using the following dial-in details:

Participants are advised to connect at least 15 minutes prior to the scheduled start time to ensure a timely connection.

Webcast Access

The live webcast will be available via a direct link on the Crinetics website or through the Events section. An archived version of the webcast will be accessible later in the Investor Relations section of www.crinetics.com .

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and endocrine-related tumors. The company specializes in discovering, developing, and commercializing novel therapies that target G-protein coupled receptors (GPCRs) with small molecules.

Its first commercial product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA and EMA for adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. The company's pipeline includes late-stage investigational candidate atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate for somatostatin receptor 2 (SST2) expressing neuroendocrine tumors.

Citizens analyst Jonathan Wolleben and HC Wainwright & Co. analyst Douglas Tsao have both reiterated their positive ratings on Crinetics Pharmaceuticals, reflecting confidence in the company's market position and future performance potential. The endorsements come as the pharmaceutical company continues its operations in the sector.

Analyst Ratings and Price Targets

Citizens has maintained its Market Outperform rating for Crinetics Pharmaceuticals, with a price target of $95. Similarly, HC Wainwright & Co. has reiterated a Buy rating, setting a price target of $81.

The $95 price target from Citizens reflects the analyst's valuation of the company's stock, while the $81 target from HC Wainwright & Co. provides a slightly more conservative outlook.